col blocks we are bridge builder col blocks
COVID answers in Scientific Journals all over the world

Elsevier: The Lancet Rheumatology
  original article Date Title Authors   All Authors
1 [GO] 2021―Jul―22 Immediate effect of the COVID-19 pandemic on patient health, health-care use, and behaviours: results from an international survey of people with rheumatic diseases Jonathan S Hausmann, Kevin Kennedy, Julia F Simard, Jean W Liew, Jeffrey A Sparks, Tarin T Moni, et al. (+146)
2 [GO] 2021―Jul―22 Adult-onset Still's disease following COVID-19 vaccination Flavia Leone, Pier Giacomo Cerasuolo, Silvia Laura Bosello, Lucrezia Verardi, Enrica Fiori, Fabrizio Cocciolillo, et al. (+3)
3 [GO] 2021―Jul―22 Adult-onset Still's disease after mRNA COVID-19 vaccine Daniel Magliulo, Soumya Narayan, Frances Ue, Afroditi Boulougoura, Fadi Badlissi
4 [GO] 2021―Jul―22 Effect of the COVID-19 pandemic on patients with systemic rheumatic diseases Alessandro Antonelli, Poupak Fallahi, Giusy Elia, Francesca Ragusa, Sabrina Rosaria Paparo, Valeria Mazzi, et al. (+3)
5 [GO] 2021―Jul―21 Tolerance of COVID-19 vaccination in patients with systemic lupus erythematosus: the international VACOLUP study Renaud Felten, Lou Kawka, Maxime Dubois, Manuel F Ugarte-Gil, Yurilis Fuentes-Silva, Matteo Piga, Laurent Arnaud
6 [GO] 2021―Jul―08 Impact of methotrexate on first-dose COVID-19 mRNA vaccination Caoilfhionn M Connolly, Julie J Paik
7 [GO] 2021―Jul―08 The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study Satveer K Mahil, Katie Bechman, Antony Raharja, Clara Domingo-Vila, David Baudry, Matthew A Brown, et al. (+15)
8 [GO] 2021―Jul―06 Reactivation of IgA vasculitis after COVID-19 vaccination Michel Obeid, Craig Fenwick, Giuseppe Pantaleo
9 [GO] 2021―Jun―18 First data on COVID-19 morbidity and mortality in patients with rheumatic disease from South Korea Karen Schreiber, Oliver Hendricks
10 [GO] 2021―Jun―18 Autoimmune inflammatory rheumatic diseases and COVID-19 outcomes in South Korea: a nationwide cohort study Youn Ho Shin, Jae Il Shin, Sung Yong Moon, Hyun Young Jin, So Young Kim, Jee Myung Yang, et al. (+15)
11 [GO] 2021―Jun―18 Adverse events after first COVID-19 vaccination in patients with autoimmune diseases Laura Boekel, Laura Y Kummer, Koos P J van Dam, Femke Hooijberg, Zoé van Kempen, Erik H Vogelzang, et al. (+11)
12 [GO] 2021―Jun―08 Inflammatory biomarkers in COVID-19-associated multisystem inflammatory syndrome in children, Kawasaki disease, and macrophage activation syndrome: a cohort study Jackeline J Rodriguez-Smith, Emely L Verweyen, Gwendolyn M Clay, Ysabella M Esteban, Sarah R de Loizaga, Elizabeth Joy Baker, et al. (+6)
13 [GO] 2021―May―28 Defining COVID-19-associated hyperinflammatory syndrome in specific populations Brandon J Webb
14 [GO] 2021―May―28 Laboratory trends, hyperinflammation, and clinical outcomes for patients with a systemic rheumatic disease admitted to hospital for COVID-19: a retrospective, comparative cohort study Tiffany Y-T Hsu, Kristin M D'Silva, Naomi J Patel, Jiaqi Wang, Alisa A Mueller, Xiaoqing Fu, et al. (+10)
15 [GO] 2021―May―27 Going viral: misinformation in the time of COVID-19 The Lancet Rheumatology
16 [GO] 2021―May―27 COVID-19 vaccination advice via SMS-based video to improve vaccination uncertainty in at-risk groups James Bateman, Natasha Cox, Lavanya Rajagopala, Mark Ford, Muhamad Jasim, Diarmuid Mulherin, et al. (+4)
17 [GO] 2021―May―27 Systemic lupus erythematosus does not prevent antibody responses to SARS-CoV-2 Martin Aringer
18 [GO] 2021―May―27 Evaluation of SARS-CoV-2 IgG antibody reactivity in patients with systemic lupus erythematosus: analysis of a multi-racial and multi-ethnic cohort Amit Saxena, Allison Guttmann, Mala Masson, Mimi Y Kim, Rebecca H Haberman, Rochelle Castillo, et al. (+78)
19 [GO] 2021―May―07 Non-steroidal anti-inflammatory drug use in COVID-19 Kristian Kragholm, Christian Torp-Pedersen, Emil Fosbol
20 [GO] 2021―May―07 Non-steroidal anti-inflammatory drug use and outcomes of COVID-19 in the ISARIC Clinical Characterisation Protocol UK cohort: a matched, prospective cohort study Thomas M Drake, Cameron J Fairfield, Riinu Pius, Stephen R Knight, Lisa Norman, Michelle Girvan, et al. (+356)
21 [GO] 2021―Apr―28 COVID-19 in patients with rheumatic disease: finally, a denominator Daniel J Wallace
22 [GO] 2021―Apr―28 SARS-CoV-2 outbreak in immune-mediated inflammatory diseases: the Euro-COVIMID multicentre cross-sectional study David Saadoun, Matheus Vieira, Mathieu Vautier, Xenofon Baraliakos, Ioana Andreica, José A P da Silva, et al. (+16)
23 [GO] 2021―Apr―19 A complex intervention to improve anxiety in people with systemic sclerosis during COVID-19 Jill M Newby
24 [GO] 2021―Apr―19 Effects of a multi-faceted education and support programme on anxiety symptoms among people with systemic sclerosis and anxiety during COVID-19 (SPIN-CHAT): a two-arm parallel, partially nested, randomised, controlled trial Brett D Thombs, Linda Kwakkenbos, Brooke Levis, Angelica Bourgeault, Richard S Henry, Alexander W Levis, et al. (+23)
25 [GO] 2021―Apr―06 Incident systemic rheumatic disease following COVID-19 Tiffany Y-T Hsu, Kristin M D'Silva, Naomi J Patel, Xiaoqing Fu, Zachary S Wallace, Jeffrey A Sparks
26 [GO] 2021―Mar―31 The role of antirheumatics in patients with COVID-19 Christoffer B Nissen, Savino Sciascia, Danieli de Andrade, Tatsuya Atsumi, Ian N Bruce, Randy Q Cron, et al. (+6)
27 [GO] 2021―Mar―31 Flare of rheumatoid arthritis after COVID-19 vaccination Katherine A Terracina, Filemon K Tan
28 [GO] 2021―Mar―27 First manifestation of adult-onset Still's disease after COVID-19 Anna D Bamidis, Philipp Koehler, Veronica di Cristanziano, Kurt Rasche, Baris Demirel, Petra Bacher, et al. (+6)
29 [GO] 2021―Mar―25 COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study Jérôme Avouac, Elodie Drumez, Eric Hachulla, Raphaèle Seror, Sophie Georgin-Lavialle, Soumaya El Mahou, et al. (+17)
30 [GO] 2021―Mar―25 Managing patients with rheumatic diseases treated with rituximab during the COVID-19 pandemic Maxime Dougados
31 [GO] 2021―Mar―19 Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial Paul C Cremer, Antonio Abbate, Kristin Hudock, Carla McWilliams, Jinesh Mehta, Steven Y Chang, et al. (+47)
32 [GO] 2021―Mar―19 COVID-19: angiotensin II in development of lung immunothrombosis and vasculitis mimics - Author's reply Dennis McGonagle, Charlie Bridgewood, Athimalaipet V Ramanan, James F M Meaney, Abdulla Watad
33 [GO] 2021―Mar―19 COVID-19: angiotensin II in development of lung immunothrombosis and vasculitis mimics Graham Lloyd-Jones, Matthijs Oudkerk
34 [GO] 2021―Mar―19 Granulocyte-macrophage colony stimulating factor in COVID-19: friend or foe? Puja Mehta, Rachel C Chambers, Lorenzo Dagna
35 [GO] 2021―Mar―19 Arthritis after SARS-CoV-2 infection Chokan Baimukhamedov, Tatiana Barskova, Marco Matucci-Cerinic
36 [GO] 2021―Mar―11 Patients with gout: an under-recognised group at high risk of COVID-19 Nicola Dalbeth, Philip C Robinson
37 [GO] 2021―Mar―09 Interleukin-1 and interleukin-6 inhibition in patients with COVID-19 and hyperinflammation Juan Salvatierra, Ismael Francisco Aomar-Millán, José Hernández-Quero
38 [GO] 2021―Mar―09 Interleukin-1 and interleukin-6 inhibition in patients with COVID-19 and hyperinflammation - Authors' reply Giulio Cavalli, Alessandro Larcher, Alessandro Tomelleri, Lorenzo Dagna
39 [GO] 2021―Feb―23 Perspective of patients with autoimmune diseases on COVID-19 vaccination Laura Boekel, Femke Hooijberg, Zoé L E van Kempen, Erik H Vogelzang, Sander W Tas, Joep Killestein, et al. (+8)
40 [GO] 2021―Feb―23 Vaccination against COVID-19: Expectations and concerns of patients with autoimmune and rheumatic diseases Renaud Felten, Maxime Dubois, Manuel F Ugarte-Gil, Aurore Chaudier, Lou Kawka, Hugo Bergier, et al. (+10)
41 [GO] 2021―Feb―06 Type I interferon, anti-interferon antibodies, and COVID-19 Leonard H Calabrese, Kevin Winthrop, Vibeke Strand, Jinoos Yazdany, Jolan E Walter
42 [GO] 2021―Feb―06 COVID-19 cytokine storm: targeting the appropriate cytokine Randy Q Cron
43 [GO] 2021―Feb―06 Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study Giulio Cavalli, Alessandro Larcher, Alessandro Tomelleri, Corrado Campochiaro, Emanuel Della-Torre, Giacomo De Luca, et al. (+14)
44 [GO] 2021―Jan―28 Too long to wait: the impact of COVID-19 on elective surgery The Lancet Rheumatology
45 [GO] 2021―Jan―28 Changing COVID-19 outcomes in patients with rheumatic disease-are we really getting better at this? Milena A Gianfrancesco, Philip C Robinson
46 [GO] 2021―Jan―27 Hydroxychloroquine treatment does not reduce COVID-19 mortality; underdosing to the wrong patients? Luis Ayerbe, Carlos Risco-Risco, Iván Núñez-Gil, Maria Perez-Piñar, Salma Ayis
47 [GO] 2021―Jan―27 Hydroxychloroquine treatment does not reduce COVID-19 mortality; underdosing to the wrong patients? - Authors' reply Christopher T Rentsch, Nicholas J DeVito, Brian MacKenna, Caroline E Morton, Krishnan Bhaskaran, Jeremy P Brown, et al. (+27)
48 [GO] 2021―Jan―19 Divergent effects of acute versus chronic glucocorticoids in COVID-19 Philip C Robinson, Eric Morand
49 [GO] 2021―Jan―14 COVID-19 and systemic sclerosis: clinicopathological implications from Italian nationwide survey study Clodoveo Ferri, Dilia Giuggioli, Vincenzo Raimondo, Lorenzo Dagna, Valeria Riccieri, Elisabetta Zanatta, et al. (+117)
50 [GO] 2021―Jan―10 COVID-19 vasculitis and novel vasculitis mimics Dennis McGonagle, Charlie Bridgewood, Athimalaipet V Ramanan, James F M Meaney, Abdulla Watad
51 [GO] 2021―Jan―10 Thromboses and COVID-19: reducing inflammation in addition to thromboprophylaxis Puja Mehta, Dorian O Haskard, Michael A Laffan, Rachel C Chambers, Beverley J Hunt
52 [GO] 2020―Dec―24 Temporal trends in severe COVID-19 outcomes in patients with rheumatic disease: a cohort study April Jorge, Kristin M D'Silva, Andrew Cohen, Zachary S Wallace, Natalie McCormick, Yuqing Zhang, Hyon K Choi
53 [GO] 2020―Dec―24 SARS-CoV-2 serological cross-reactivity with autoantibodies Kay Weng Choy
54 [GO] 2020―Dec―24 SARS-CoV-2 serological cross-reactivity with autoantibodies - Authors' reply Jialin Teng, Jin Dai
55 [GO] 2020―Dec―17 Genetic IL-6R variants and therapeutic inhibition of IL-6 receptor signalling in COVID-19 Christoph Garbers, Stefan Rose-John
56 [GO] 2020―Dec―17 Genetic IL-6R variants and therapeutic inhibition of IL-6 receptor signalling in COVID-19 - Authors' reply Jonas Bovijn, Cecilia M Lindgren, Michael V Holmes
57 [GO] 2020―Dec―16 Efficacy matters: broadening complement inhibition in COVID-19 Dimitrios C Mastellos, Panagiotis Skendros, Rodrigo T Calado, Antonio M Risitano, John D Lambris
58 [GO] 2020―Dec―16 Efficacy matters: broadening complement inhibition in COVID-19 - Authors' reply Alexander P J Vlaar, Sanne de Bruin, Matthijs C Brouwer, Diederik van de Beek
59 [GO] 2020―Dec―09 Clinical pathways for patients with giant cell arteritis during the COVID-19 pandemic: an international perspective Sarah L Mackie, Elisabeth Brouwer, Richard Conway, Kornelis S M van der Geest, Puja Mehta, Susan P Mollan, et al. (+4)
60 [GO] 2020―Dec―03 Variability in counselling for adrenal insufficiency in COVID-19 and beyond: a survey of rheumatology practice Puja Mehta, Karim Meeran, Elizabeth Macphie, Afroze Abbas, Jonathan Rippin, Rachel C Jeffery, et al. (+5)
61 [GO] 2020―Dec―01 COVID-19 in axial spondyloarthritis care provision: helping to straighten the long and winding road Helena Marzo-Ortega, Simon Whalley, Jill Hamilton, Dale Webb
62 [GO] 2020―Nov―24 First flare of ACPA-positive rheumatoid arthritis after SARS-CoV-2 infection Lea Perrot, Marie Hemon, Jean-Marc Busnel, Olivier Muis-Pistor, Christophe Picard, Christine Zandotti, et al. (+4)
63 [GO] 2020―Nov―10 Influenza vaccination and interruption of methotrexate in adult patients in the COVID-19 era: an ongoing dilemma Puja Mehta, Emilie Sanchez, Elena Moraitis, Nicky Longley, Dennis W Lendrem, Ian P Giles, et al. (+3)
64 [GO] 2020―Nov―06 Hydroxychloroquine in the prevention of COVID-19 mortality April Jorge
65 [GO] 2020―Nov―06 Effect of pre-exposure use of hydroxychloroquine on COVID-19 mortality: a population-based cohort study in patients with rheumatoid arthritis or systemic lupus erythematosus using the OpenSAFELY platform Christopher T Rentsch, Nicholas J DeVito, Brian MacKenna, Caroline E Morton, Krishnan Bhaskaran, Jeremy P Brown, et al. (+27)
66 [GO] 2020―Oct―30 Hydroxychloroquine in patients with rheumatic diseases during the COVID-19 pandemic: a letter to clinicians Karen Schreiber, Savino Sciascia, Ian N Bruce, Ian Giles, Maria J Cuadrado, Hannah Cohen, et al. (+13)
67 [GO] 2020―Oct―09 Imperfect storm: is interleukin-33 the Achilles heel of COVID-19? Gaetano Zizzo, Philip L Cohen
68 [GO] 2020―Oct―05 Viral arthritis and COVID-19 Simone Parisi, Richard Borrelli, Sabina Bianchi, Enrico Fusaro
69 [GO] 2020―Sep―30 COVID-19 and African rheumatology: progress in adversity Richard O Akintayo, Asgar Kalla, Adewale Adebajo
70 [GO] 2020―Sep―29 Defining the scourge of COVID-19 hyperinflammatory syndrome Randy Q Cron, Grant S Schulert, Rachel S Tattersall
71 [GO] 2020―Sep―29 Clinical criteria for COVID-19-associated hyperinflammatory syndrome: a cohort study Brandon J Webb, Ithan D Peltan, Paul Jensen, Daanish Hoda, Bradley Hunter, Aaron Silver, et al. (+9)
72 [GO] 2020―Sep―28 The opening salvo of anti-complement therapy against COVID-19 Courtney M Campbell
73 [GO] 2020―Sep―28 Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial Alexander P J Vlaar, Sanne de Bruin, Matthias Busch, Sjoerd A M E G Timmermans, Ingeborg E van Zeggeren, Rutger Koning, et al. (+20)
74 [GO] 2020―Sep―25 Genetic variants mimicking therapeutic inhibition of IL-6 receptor signaling and risk of COVID-19 Jonas Bovijn, Cecilia M Lindgren, Michael V Holmes
75 [GO] 2020―Sep―24 High-stakes heterogeneity in COVID-19 The Lancet Rheumatology
76 [GO] 2020―Sep―21 The contribution of the observational research design to COVID-19 research Alfred H J Kim, Seth A Eisen
77 [GO] 2020―Sep―21 Long-term hydroxychloroquine use in patients with rheumatic conditions and development of SARS-CoV-2 infection: a retrospective cohort study Chris A Gentry, Mary Beth Humphrey, Sharanjeet K Thind, Sage C Hendrickson, George Kurdgelashvili, Riley J Williams
78 [GO] 2020―Sep―17 Tocilizumab in COVID-19: finding the optimal route and dose Siddharth Jain, Sanjay Jain, Shefali Khanna Sharma
79 [GO] 2020―Sep―17 Tocilizumab in COVID-19: finding the optimal route and dose - Authors' reply Giovanni Guaraldi, Jovana Milic, Alessandro Cozzi-Lepri, Federico Pea, Cristina Mussini
80 [GO] 2020―Sep―09 COVACTA trial raises questions about tocilizumab's benefit in COVID-19 Bryant Furlow
81 [GO] 2020―Sep―06 Mavrilimumab for severe COVID-19 Adil Rashid Khan, Manish Soneja, Praveen Kumar Tirlangi, Naveet Wig
82 [GO] 2020―Sep―06 Mavrilimumab for severe COVID-19 Mohamad Amin Pourhoseingholi, Sajad Shojaee, Sara Ashtari
83 [GO] 2020―Sep―06 Mavrilimumab for severe COVID-19 - Authors' reply Giacomo De Luca, Giulio Cavalli, Corrado Campochiaro, Emanuel Della-Torre, Lorenzo Dagna
84 [GO] 2020―Sep―06 Accumulating evidence suggests anti-TNF therapy needs to be given trial priority in COVID-19 treatment Philip C Robinson, Duncan Richards, Helen L Tanner, Marc Feldmann
85 [GO] 2020―Aug―27 Patients with rheumatic diseases adhere to COVID-19 isolation measures more strictly than the general population Femke Hooijberg, Laura Boekel, Erik H Vogelzang, Maureen Leeuw, Maarten Boers, Ronald van Vollenhoven, et al. (+3)
86 [GO] 2020―Aug―21 Delving beneath the surface of hyperinflammation in COVID-19 Kiran Reddy, Angela J Rogers, Daniel F McAuley
87 [GO] 2020―Aug―21 COVID-19-associated hyperinflammation and escalation of patient care: a retrospective longitudinal cohort study Jessica J Manson, Colin Crooks, Meena Naja, Amanda Ledlie, Bethan Goulden, Trevor Liddle, et al. (+30)
88 [GO] 2020―Aug―17 Tocilizumab for severe COVID-19 pneumonia Jean-Jacques Mourad, Philippe Azria
89 [GO] 2020―Aug―17 Tocilizumab for severe COVID-19 pneumonia Salvatore Piano, Roberto Vettor, Paolo Angeli, G Arcidiacono, D Benfaremo, S Bettini, et al. (+25)
90 [GO] 2020―Aug―17 Tocilizumab for severe COVID-19 pneumonia Brian J Lipworth, Rory Chan, Chris RuiWen Kuo
91 [GO] 2020―Aug―17 Tocilizumab for severe COVID-19 pneumonia - Authors' reply Giovanni Guaraldi, Marianna Meschiari, Jovana Milic, Alessandro Cozzi-Lepri, Cristina Mussini
92 [GO] 2020―Aug―14 The conundrum of interleukin-6 blockade in COVID-19 Corrado Campochiaro, Lorenzo Dagna
93 [GO] 2020―Aug―14 Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study Noa Biran, Andrew Ip, Jaeil Ahn, Ronaldo C Go, Shuqi Wang, Shivam Mathura, et al. (+23)
94 [GO] 2020―Aug―07 Anakinra for severe forms of COVID-19 Adil Rashid Khan, Manish Soneja, Netto George, Naveet Wig
95 [GO] 2020―Aug―07 Anakinra for severe forms of COVID-19 Laine Marc, Bonello Laurent
96 [GO] 2020―Aug―07 Anakinra for severe forms of COVID-19 Naim Akhtar Khan
97 [GO] 2020―Aug―07 Anakinra for severe forms of COVID-19 - Authors' reply Gilles Hayem, Thomas Huet, Stéphane Jouveshomme, Hélène Beaussier, Gilles Chatellier, Jean-Jacques Mourad
98 [GO] 2020―Jul―31 B-cell depletion with rituximab in the COVID-19 pandemic: where do we stand? Puja Mehta, Joanna C Porter, Rachel C Chambers, David A Isenberg, Venkat Reddy
99 [GO] 2020―Jul―29 Opioid use in rheumatic diseases: preventing another pandemic The Lancet Rheumatology
100 [GO] 2020―Jul―24 Effect of anakinra in COVID-19 Emma J Kooistra, Nicole J B Waalders, Matthijs Kox, Peter Pickkers
101 [GO] 2020―Jul―24 Effect of anakinra in COVID-19 - Authors' reply Giulio Cavalli, Lorenzo Dagna
102 [GO] 2020―Jul―13 Symmetric peripheral polyarthritis developed during SARS-CoV-2 infection Rosaria Talarico, Chiara Stagnaro, Francesco Ferro, Linda Carli, Marta Mosca
103 [GO] 2020―Jul―10 Severe refractory Kawasaki disease in seven infants in the COVID-19 era Stefania Vergnano, Nele Alders, Catherine Armstrong, Andrew R Bamber, Srini Bandi, Jennifer A Evans, et al. (+7)
104 [GO] 2020―Jul―10 Iloprost for COVID-19-related vasculopathy Carine J Moezinia, Antonio Ji-Xu, Arianna Azari, Serena Horlick, Christopher Denton, Richard Stratton
105 [GO] 2020―Jul―03 COVID-19 in patients with rheumatic disease in Hubei province, China: a multicentre retrospective observational study Jixin Zhong, Guifen Shen, Huiqin Yang, Anbin Huang, Xiaoqi Chen, Li Dong, et al. (+14)
106 [GO] 2020―Jun―29 COVID-19 in children and young people Susanna Felsenstein, Christian M Hedrich
107 [GO] 2020―Jun―29 Pulmonary intravascular coagulopathy in COVID-19 pneumonia Hisyovi Cárdenas Suri
108 [GO] 2020―Jun―29 Pulmonary intravascular coagulopathy in COVID-19 pneumonia Giovanni Brondani, Luca Apollonio, Elisa Gremese, Gianfranco Ferraccioli
109 [GO] 2020―Jun―29 Pulmonary intravascular coagulopathy in COVID-19 pneumonia Brandon P Reines, Barry W Ninham
110 [GO] 2020―Jun―29 Pulmonary intravascular coagulopathy in COVID-19 pneumonia - Authors' reply Dennis McGonagle, James S O'Donnell, Kassem Sharif, Paul Emery, Charles Bridgewood
111 [GO] 2020―Jun―25 Anakinra for patients with COVID-19 Omar Maoujoud, Mohammed Asserraji, Samir Ahid, Marouane Belarbi, Nadir Zemraoui
112 [GO] 2020―Jun―25 Anakinra for patients with COVID-19 Xavier Valette, Damien du Cheyron
113 [GO] 2020―Jun―25 Anakinra for patients with COVID-19 Nicolas Martin-Silva, Hubert de Boysson, Achille Aouba
114 [GO] 2020―Jun―25 Anakinra for patients with COVID-19 - Authors' reply Giulio Cavalli, Giovanni Landoni, Alberto Zangrillo, Lorenzo Dagna
115 [GO] 2020―Jun―24 Tocilizumab in patients with severe COVID-19: a retrospective cohort study Giovanni Guaraldi, Marianna Meschiari, Alessandro Cozzi-Lepri, Jovana Milic, Roberto Tonelli, Marianna Menozzi, et al. (+28)
116 [GO] 2020―Jun―24 Can tocilizumab calm the cytokine storm of COVID-19? Grant S Schulert
117 [GO] 2020―Jun―18 COVID-19 in patients with rheumatic diseases in northern Italy: a single-centre observational and case-control study Micaela Fredi, Ilaria Cavazzana, Liala Moschetti, Laura Andreoli, Franco Franceschini, Paolo Airò, et al. (+17)
118 [GO] 2020―Jun―16 GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study Giacomo De Luca, Giulio Cavalli, Corrado Campochiaro, Emanuel Della-Torre, Piera Angelillo, Alessandro Tomelleri, et al. (+16)
119 [GO] 2020―Jun―16 GM-CSF in the treatment of COVID-19: a new conductor in the pathogenesis of cytokine storm? Ennio Giulio Favalli, Roberto Caporali
120 [GO] 2020―Jun―08 Are treat-to-target and dose tapering strategies for rheumatoid arthritis possible during the COVID-19 pandemic? Su-Ann Yeoh, Michael R Ehrenstein
121 [GO] 2020―Jun―04 Canakinumab in a subgroup of patients with COVID-19 Claudio Ucciferri, Antonio Auricchio, Marta Di Nicola, Nicola Potere, Antonio Abbate, Francesco Cipollone, et al. (+2)
122 [GO] 2020―Jun―01 Self-risk assessment for patients with rheumatic disease during the COVID-19 pandemic Helena Marzo-Ortega, Ai Lyn Tan, Lesley-Anne Bissell, Ann W Morgan, Claire Vandevelde, Edward M Vital, Shouvik Dass
123 [GO] 2020―May―29 Anakinra for severe forms of COVID-19: a cohort study Thomas Huet, Hélène Beaussier, Olivier Voisin, Stéphane Jouveshomme, Gaëlle Dauriat, Isabelle Lazareth, et al. (+11)
124 [GO] 2020―May―29 Coronavirus is the trigger, but the immune response is deadly Randy Q Cron
125 [GO] 2020―May―27 Hydroxychloroquine: balancing the needs of LMICs during the COVID-19 pandemic Soumya Banerjee
126 [GO] 2020―May―27 COVID-19: a time to reflect The Lancet Rheumatology
127 [GO] 2020―May―26 COVID-19 and systemic lupus erythematosus: a case series Yevgeniya Gartshteyn, Anca D Askanase, Nancyanne M Schmidt, Elana J Bernstein, Leila Khalili, Rachel Drolet, et al. (+3)
128 [GO] 2020―May―21 Anakinra in COVID-19: important considerations for clinical trials Andrew King, Andy Vail, Claire O'Leary, Cathal Hannan, David Brough, Hiren Patel, et al. (+6)
129 [GO] 2020―May―21 The immunology of COVID-19: is immune modulation an option for treatment? Jixin Zhong, Jungen Tang, Cong Ye, Lingli Dong
130 [GO] 2020―May―18 Detection of IgM and IgG antibodies against SARS-CoV-2 in patients with autoimmune diseases Jialin Teng, Jin Dai, Yutong Su, Zhuochao Zhou, Huihui Chi, Liyan Wan, et al. (+12)
131 [GO] 2020―May―16 Novel paediatric presentation of COVID-19 with ARDS and cytokine storm syndrome without respiratory symptoms Clare E Pain, Susanna Felsenstein, Gavin Cleary, Sarah Mayell, Karsten Conrad, Srikrishna Harave, et al. (+4)
132 [GO] 2020―May―07 Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study Giulio Cavalli, Giacomo De Luca, Corrado Campochiaro, Emanuel Della-Torre, Marco Ripa, Diana Canetti, et al. (+17)
133 [GO] 2020―May―07 Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia Dennis McGonagle, James S O'Donnell, Kassem Sharif, Paul Emery, Charles Bridgewood
134 [GO] 2020―May―07 Should COVID-19 take advice from rheumatologists? Kate F Kernan, Scott W Canna
135 [GO] 2020―May―06 Rapid distribution of information by SMS-embedded video link to patients during a pandemic James Bateman, Diarmuid Mulherin, George Hirsch, Srinivasan Venkatachalam, Tom Sheeran
136 [GO] 2020―May―05 Initial data from the COVID-19 Global Rheumatology Alliance provider registries Anthony Vanjak
137 [GO] 2020―May―05 Initial data from the COVID-19 Global Rheumatology Alliance provider registries - Authors' reply Milena A Gianfrancesco
138 [GO] 2020―Apr―16 Rheumatic disease and COVID-19: initial data from the COVID-19 Global Rheumatology Alliance provider registries Milena A Gianfrancesco, Kimme L Hyrich, Laure Gossec, Anja Strangfeld, Loreto Carmona, Elsa F Mateus, et al. (+11)
139 [GO] 2020―Apr―16 Unity amidst uncertainty: COVID-19 pandemic fosters collaboration in rheumatology community The Lancet Rheumatology
140 [GO] 2020―Apr―06 Global rheumatology in the time of COVID-19 Laura B Lewandowski, Evelyn Hsieh
141 [GO] 2020―Apr―06 Preventing COVID-19-induced pneumonia with anticytokine therapy Giovanni Monteleone, Pier Carlo Sarzi-Puttini, Sandro Ardizzone
142 [GO] 2020―Apr―04 Rheumatologists rapidly adjust patient care during COVID-19 pandemic Tony Kirby
143 [GO] 2020―Apr―02 Caution and clarity required in the use of chloroquine for COVID-19 Yin Kwan Wong, Jing Yang, Yingke He
144 [GO] 2020―Apr―01 Excitement around hydroxychloroquine for treating COVID-19 causes challenges for rheumatology Brian Owens


[de][en]

Last change 2021―Jun―30 20:09:44 UTC

© Daten-Quadrat 2021       Done in 0.021 sec